Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zavegepant for Hospitalized COVID-19
NCT04346615Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Apr 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Zavegepant with Placebo (2 arms). Primary endpoint: Mean 6 Point Ordinal Severity Rating Scale Score at Day 15. Started Apr 2020; status: terminated.
02
Drugs
zavegepant
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04346615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04346615.